Correction
Published on 19 Dec 2024
Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
- 832 views
Correction
Published on 19 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Case Report
Published on 17 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 17 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 17 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 16 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Opinion
Published on 16 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 13 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 13 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 10 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Review
Published on 06 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Case Report
Published on 05 Dec 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 28 Nov 2024
in Multiple Sclerosis and Neuroimmunology
Review
Published on 27 Nov 2024
in Multiple Sclerosis and Neuroimmunology
Case Report
Published on 25 Nov 2024
in Multiple Sclerosis and Neuroimmunology
Review
Published on 22 Nov 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 20 Nov 2024
in Multiple Sclerosis and Neuroimmunology